Richard  Kuntz net worth and biography

Richard Kuntz Biography and Net Worth

SVP of Medtronic
Dr. Rick Kuntz is Senior Vice President, Chief Medical and Scientific Officer of Medtronic and serves as a member of the Company’s Executive Committee. In this role, Kuntz oversees the company’s medical affairs, health policy and reimbursement, clinical research activities, and corporate technology.

Kuntz joined Medtronic in October 2005, as Senior Vice President and President of Medtronic Neuromodulation, which encompasses the company’s products and therapies used in the treatment of chronic pain, movement disorders, spasticity, overactive bladder and urinary retention, benign prostatic hyperplasia, and gastroparesis. In this role he was responsible for the research, development, operations and product sales and marketing for each of these therapeutic areas worldwide.

Kuntz brings to Medtronic a broad background and expertise in many different areas of healthcare. Prior to Medtronic he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute (HCRI), a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the United States Food and Drug Administration (FDA). Kuntz has directed over 100 multicenter clinical trials and has authored more than 250 original publications. His major interests are traditional and alternative clinical trial design and biostatistics.

Kuntz also served as Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics, and an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston, MA. Kuntz has served as a member of the Board of Governors of PCORI (Patient Centered Outcomes Research Institute) since it was established in 2010 as part of the Affordable Care Act.

Kuntz graduated from Miami University, and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Kuntz received his Master’s of science in biostatistics from the Harvard School of Public Health.

What is Richard Kuntz's net worth?

The estimated net worth of Richard Kuntz is at least $6.69 million as of September 27th, 2019. Mr. Kuntz owns 78,916 shares of Medtronic stock worth more than $6,687,342 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Kuntz may own. Learn More about Richard Kuntz's net worth.

How do I contact Richard Kuntz?

The corporate mailing address for Mr. Kuntz and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Richard Kuntz's contact information.

Has Richard Kuntz been buying or selling shares of Medtronic?

Richard Kuntz has not been actively trading shares of Medtronic during the last ninety days. Most recently, Richard Kuntz sold 21,425 shares of the business's stock in a transaction on Friday, September 27th. The shares were sold at an average price of $107.51, for a transaction totalling $2,303,401.75. Following the completion of the sale, the senior vice president now directly owns 78,916 shares of the company's stock, valued at $8,484,259.16. Learn More on Richard Kuntz's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 4 times. They sold a total of 55,659 shares worth more than $4,695,766.41. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Richard Kuntz Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/27/2019Sell21,425$107.51$2,303,401.7578,916View SEC Filing Icon  
7/22/2019Sell3,438$101.12$347,650.56View SEC Filing Icon  
8/28/2018Sell47,176$95.88$4,523,234.88152,579View SEC Filing Icon  
6/8/2018Sell11,500$87.13$1,001,995.00View SEC Filing Icon  
1/9/2018Sell78,526$86.21$6,769,726.46149,761View SEC Filing Icon  
9/27/2016Sell17,141$86.70$1,486,124.70149,425View SEC Filing Icon  
9/26/2016Sell25,199$86.67$2,183,997.33149,425View SEC Filing Icon  
6/3/2016Sell49,905$82.60$4,122,153.00127,647View SEC Filing Icon  
4/1/2016Sell4,000$75.22$300,880.00104,358View SEC Filing Icon  
12/4/2015Sell13,715$78.06$1,070,592.90108,086View SEC Filing Icon  
4/6/2015Sell31,768$77.39$2,458,525.52View SEC Filing Icon  
12/19/2014Sell12,855$74.54$958,211.70View SEC Filing Icon  
4/9/2014Sell2,512$60.98$153,181.76104,736View SEC Filing Icon  
See Full Table

Richard Kuntz Buying and Selling Activity at Medtronic

This chart shows Richard Kuntz's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $84.74
Low: $83.92
High: $85.13

50 Day Range

MA: $89.17
Low: $84.11
High: $92.27

2 Week Range

Now: $84.74
Low: $75.96
High: $92.68

Volume

5,550,747 shs

Average Volume

6,270,891 shs

Market Capitalization

$108.68 billion

P/E Ratio

25.91

Dividend Yield

3.29%

Beta

0.84